HYTERA
28.3.2022 08:02:10 CEST | Business Wire | Press release
Hytera (SZSE: 002583), the global leading provider of professional communications equipment and solutions, is delighted to announce the launch of its next generation H Series of DMR terminals, designed to meet and exceed the increasingly complex and demanding communication challenges facing public safety, energy, transportation, utilities, commercial and other industry verticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005001/en/
Built for Customer Success
The newly developed hardware platform and software architecture delivers improved radio performance and optimises the user experience to provide more intuitive, practical, and easy to use functionality. This allows users to focus on the task in hand and provide better, safer and more efficient outcomes for the organisations and communities they serve.
Lighter, Slimmer and More Powerful
The new hand portables comprise the HP7 Series (HP78X/HP70X) and the HP6 Series (HP68X/HP60X) radios. They are more compact, lighter and deliver increased battery capacity and battery life. The radios provide enhanced audio clarity and loudness thanks to a combination of high-performance speakers and DSP algorithm, while embedded AI noise cancellation makes the audio even clearer.
Impressive New Features
Other innovations include using the vibration of the speaker to expel water through a specially designed cavity to ensure clear audio even in torrential weather. Direct mode communication range is extended by 25% in open environments, while signal quality is improved at the edge of the network when in trunking mode.
The HM78X mobile radio delivers similar performance enhancements as the portable terminals. New highlights include an optimised control head-mounting solution that supports flexible deployment options. The inclusion of an Ethernet port allows the radio to function as a gateway for narrowband networking, while also supporting the easy addition of new features from third-party companies and platforms.
The HR106X compact digital repeater completes the latest line-up. Despite being half the size of its predecessor, Hytera has managed to integrate a telephone gateway, router and power adapter inside this versatile repeater to provide an all-in-one solution.
Hytera users depend on the ingenuity and advancement that only Hytera can deliver, to help them carry out the most demanding tasks in challenging environments. Hytera’s H Series solutions are designed for optimum performance that is more powerful, more capable and even easier to use than ever before, enabling users to respond and achieve.
Hytera held its global online launch event on March 24th during which it introduced and demonstrated the brand-new H Series and business radio series AP/BP. It also shared insights on PMR industry trends and expertise on professional communications at the event.
Watch the recorded event here: https://bit.ly/3urgQfg
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005001/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
